Skip to main content

PDGFB in breast cancer initiation, progression, and metastasis

PDGFB in Breast Cancer Initiation,Progression, and Metastasis - A cross journal collection

Submission deadline: 31 May 2022

The family of platelet derived growth factors (PDGF) encompasses proangiogenic factors, which have been associated with progression of malignancies, including breast cancer. Recent studies indicated that expression of PDGFB is an important prognostic factor in certain breast cancer types, and that combination of PDGFR inhibitors with targeted therapy could significantly increase survival. In this cross-journal collection, we welcome a wide range of articles on the role of PDGFB in mammary gland development, breast cancer initiation, progression, and metastasis, including primary research articles, reviews, and perspectives. 

To express your interest to contribute, please contact the Editor-in-Chief of the respective journal:

Breast Cancer Research: Lewis A. Chodosh (chodosh@pennmedicine.upenn.edu)
Journal of Mammary Gland Biology and Neoplasia: Zuzana Koledova (koledova@med.muni.cz)
Breast Cancer Research & Treatment: William J. Gradishar (w-gradishar@northwestern.edu)


Participating journals:
Breast Cancer Research: Submit here

Breast Cancer Research and Treatment: Submit here

Journal of Mammary Gland Biology and Neoplasia: Submit here


  1. Premenopausal, high-risk, hormone receptor-positive breast cancer patients are often treated with ovarian suppression in combination with aromatase inhibitors (AI). This combination has important adverse effec...

    Authors: Patrícia Taranto, Diogo de Brito Sales, Fernando Cotait Maluf, Rafael Aliosha Kaliks Guendelmann, Luciano de Melo Pompei, Alessandro Leal, Antonio Carlos Buzaid and Gustavo Schvartsman
    Citation: Breast Cancer Research 2024 26:133
    Content type: Research Published on:

  2. Changes in microcirculation of axillary lymph nodes (ALNs) may indicate metastasis. Reliable noninvasive imaging technique to quantify such variations is lacking. We aim to develop and investigate a contrast-f...

    Authors: Giulia Ferroni, Soroosh Sabeti, Tasneem Abdus-Shakur, Lorenzo Scalise, Jodi M. Carter, Robert T. Fazzio, Nicholas B. Larson, Mostafa Fatemi and Azra Alizad
    Citation: Breast Cancer Research 2023 25:65
    Content type: Research Published on:

  3. Breast cancer (BC) has been ranked the most common malignant tumor throughout the world and is also a leading cause of cancer-related deaths among women. SRC family kinases (SFKs) belong to the non-receptor ty...

    Authors: Juan Luo, Hailin Zou, Yibo Guo, Tongyu Tong, Liping Ye, Chengming Zhu, Liang Deng, Bo Wang, Yihang Pan and Peng Li
    Citation: Breast Cancer Research 2022 24:99
    Content type: Review Published on:

  4. The tumor immune microenvironment (TIME) generated by cancer-infiltrating immune cells has a crucial role in promoting or suppressing breast cancer progression. However, whether the steroid receptor coactivato...

    Authors: Sang Jun Han, Nuri Sung, Jin Wang, Bert W. O’Malley and David M. Lonard
    Citation: Breast Cancer Research 2022 24:73
    Content type: Research Published on:

  5. Locally advanced breast cancer (LABC), the most aggressive form of the disease, is a serious threat for women's health worldwide. The AU-rich RNA-binding factor 1 (AUF1) promotes the formation of chemo-resista...

    Authors: Taher Al-Tweigeri, Noura N. AlRaouji, Asma Tulbah, Maria Arafah, Mouad Aboussekhra, Falah Al-Mohanna, Ahmed Mostafa Gad, Abdelmonneim M. Eldali, Tusneem A. Elhassan and Abdelilah Aboussekhra
    Citation: Breast Cancer Research 2022 24:46
    Content type: Research Published on: